

A Brett Hauber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8679274/publications.pdf>

Version: 2024-02-01

110
papers

5,072
citations

185998

28
h-index

98622

67
g-index

111
all docs

111
docs citations

111
times ranked

4806
citing authors

#	ARTICLE	IF	CITATIONS
1	Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. <i>Value in Health</i> , 2011, 14, 403-413.	0.1	1,342
2	Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. <i>Value in Health</i> , 2016, 19, 300-315.	0.1	782
3	Conjoint Analysis Applications in Health — How are Studies being Designed and Reported?. <i>Patient</i> , 2010, 3, 249-256.	1.1	272
4	Incorporating patient-preference evidence into regulatory decision making. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2984-2993.	1.3	182
5	Factors That Affect Adherence to Bipolar Disorder Treatments. <i>Medical Care</i> , 2007, 45, 545-552.	1.1	124
6	Patients'™ preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis. <i>Lung Cancer</i> , 2012, 77, 224-231.	0.9	119
7	Quantifying Benefit—Risk Preferences for Medical Interventions: An Overview of a Growing Empirical Literature. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 319-329.	1.0	106
8	A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. <i>Value in Health</i> , 2016, 19, 746-750.	0.1	106
9	Hypothetical bias, cheap talk, and stated willingness to pay for health care. <i>Journal of Health Economics</i> , 2009, 28, 894-901.	1.3	88
10	Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 531-542.	0.7	88
11	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. <i>Journal of Managed Care Pharmacy</i> , 2010, 16, 616-628.	2.2	61
12	Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine. <i>Clinical Therapeutics</i> , 2000, 22, 439-451.	1.1	59
13	Stated Preferences of Patients with Cancer for Health-related Quality-of-life (HRQOL) Domains During Treatment. <i>Quality of Life Research</i> , 2006, 15, 273-283.	1.5	59
14	Stated Preference for Cancer Screening: A Systematic Review of the Literature, 1990—2013. <i>Preventing Chronic Disease</i> , 2016, 13, E27.	1.7	54
15	Eliciting Benefit—Risk Preferences and Probability-Weighted Utility Using Choice-Format Conjoint Analysis. <i>Medical Decision Making</i> , 2011, 31, 469-480.	1.2	53
16	Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA. <i>Rheumatology and Therapy</i> , 2019, 6, 461-471.	1.1	52
17	Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. <i>Value in Health</i> , 2018, 21, 59-68.	0.1	51
18	Risking Health to Avoid Injections: Preferences of Canadians with type 2 diabetes. <i>Diabetes Care</i> , 2005, 28, 2243-2245.	4.3	48

#	ARTICLE	IF	CITATIONS
19	A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 251-262.	0.9	46
20	Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma. <i>Pharmacoeconomics</i> , 2011, 29, 977-988.	1.7	44
21	Are Chemotherapy Patients' HRQoL Importance Weights Consistent with Linear Scoring Rules? A Stated-choice Approach. <i>Quality of Life Research</i> , 2006, 15, 285-298.	1.5	42
22	Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. <i>Patient Preference and Adherence</i> , 2013, 7, 937.	0.8	42
23	Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinoma. <i>Journal of Medical Economics</i> , 2012, 15, 1139-1148.	1.0	36
24	Patient preferences and assessment of likely adherence to hepatitis C virus treatment. <i>Journal of Viral Hepatitis</i> , 2011, 18, 619-627.	1.0	34
25	Quantifying Women's Stated Benefit-Risk Trade-Off Preferences for IBS Treatment Outcomes. <i>Value in Health</i> , 2010, 13, 418-423.	0.1	33
26	Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom. <i>Supportive Care in Cancer</i> , 2015, 23, 21-28.	1.0	33
27	A Survey of Patient Preferences for Oral Antihyperglycemic Therapy in Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2015, 6, 75-84.	1.2	32
28	Using the Threshold Technique to Elicit Patient Preferences: An Introduction to the Method and an Overview of Existing Empirical Applications. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 31-46.	1.0	31
29	Benefits, Risk, and Uncertainty: Preferences of Antiretroviral-Naïve African Americans for HIV Treatments. <i>AIDS Patient Care and STDs</i> , 2009, 23, 29-34.	1.1	30
30	Patients' Willingness to Trade Off Between the Duration and Frequency of Rheumatoid Arthritis Treatments. <i>Arthritis Care and Research</i> , 2014, 66, 1008-1015.	1.5	30
31	Older Americans' Risk-benefit Preferences for Modifying the Course of Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2009, 23, 23-32.	0.6	27
32	Using the Incremental Net Benefit Framework for Quantitative Benefit-Risk Analysis in Regulatory Decision-Making: A Case Study of Alosetron in Irritable Bowel Syndrome. <i>Value in Health</i> , 2010, 13, 411-417.	0.1	27
33	The value to patients of reducing lesion severity in plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2011, 22, 266-275.	1.1	27
34	Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. <i>Current Medical Research and Opinion</i> , 2014, 30, 1733-1741.	0.9	27
35	Patient and physician preferences for ulcerative colitis treatments in the United States. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 263-278.	1.0	27
36	Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. <i>Haemophilia</i> , 2021, 27, 129-136.	1.0	27

#	ARTICLE	IF	CITATIONS
37	The Effect of Nesting Structure Specification on Welfare Estimation in a Random Utility Model of Recreation Demand: An Application to the Demand for Recreational Fishing. <i>American Journal of Agricultural Economics</i> , 2000, 82, 501-514.	2.4	25
38	Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta ₂ -agonist maintenance medications. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 139-147.	1.0	24
39	Women's Willingness to Accept Perceived Risks for Vasomotor Symptom Relief. <i>Journal of Women's Health</i> , 2007, 16, 1028-1040.	1.5	23
40	Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions: An Application to Vasomotor Symptoms. <i>Value in Health</i> , 2009, 12, 146-152.	0.1	23
41	Estimating importance weights for the IWQOL-Lite using conjoint analysis. <i>Quality of Life Research</i> , 2010, 19, 701-709.	1.5	23
42	Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. <i>Quality of Life Research</i> , 2014, 23, 1813-1821.	1.5	23
43	Preferences for Multiple Sclerosis Treatments. <i>International Journal of MS Care</i> , 2017, 19, 172-183.	0.4	23
44	Who pays attention in stated-choice surveys?. <i>Health Economics (United Kingdom)</i> , 2010, 19, 111-118.	0.8	22
45	How Do Physicians Weigh Benefits and Risks Associated with Treatments in Patients with Osteoarthritis in the United Kingdom?. <i>Journal of Rheumatology</i> , 2012, 39, 1056-1063.	1.0	22
46	Physicians' Preferences for Bone Metastases Drug Therapy in the United States. <i>Value in Health</i> , 2015, 18, 78-83.	0.1	22
47	Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy. <i>Journal of Dermatological Treatment</i> , 2015, 26, 507-513.	1.1	22
48	Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2127-2139.	0.8	22
49	Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1449-1458.	1.1	22
50	Patient preferences for treatments to delay bone metastases. <i>Prostate</i> , 2014, 74, 1488-1497.	1.2	20
51	Patient Preferences and Linear Scoring Rules for Patient-Reported Outcomes. <i>Patient</i> , 2010, 3, 217-227.	1.1	19
52	Too many attributes: A test of the validity of combining discrete-choice and best"worst scaling data. <i>Journal of Choice Modelling</i> , 2015, 15, 1-13.	1.2	19
53	Artificial intelligence in breast cancer screening: primary care provider preferences. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 1117-1124.	2.2	19
54	Comparing Patient and Physician Risk Tolerance for Bleeding Events Associated with Anticoagulants in Atrial Fibrillation"evidence from the United States and Japan. <i>Value in Health Regional Issues</i> , 2015, 6, 65-72.	0.5	18

#	ARTICLE	IF	CITATIONS
55	The Ball is in Your Court: Agenda for Research to Advance the Science of Patient Preferences in the Regulatory Review of Medical Devices in the United States. <i>Patient</i> , 2017, 10, 531-536.	1.1	18
56	Colorectal Cancer Screening: Preferences, Past Behavior, and Future Intentions. <i>Patient</i> , 2018, 11, 599-611.	1.1	18
57	Patients' Benefit-Risk Preferences for Chronic Idiopathic Thrombocytopenic Purpura Therapies. <i>Annals of Pharmacotherapy</i> , 2010, 44, 479-488.	0.9	17
58	Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches. <i>Pharmacoeconomics</i> , 2020, 38, 593-606.	1.7	17
59	Healthy-years equivalent: wounded but not yet dead. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 265-269.	0.7	16
60	Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST). <i>Patient Preference and Adherence</i> , 2011, 5, 307.	0.8	15
61	Estimating the value of medical treatments to patients using probabilistic multi criteria decision analysis. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 102.	1.5	15
62	Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. <i>Cancer Management and Research</i> , 2017, Volume 9, 149-158.	0.9	15
63	Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. <i>Arthritis Research and Therapy</i> , 2018, 20, 102.	1.6	15
64	The relationship between health perception and utility in heart failure patients in a clinical trial: results from an OVERTURE substudy. <i>Journal of Cardiac Failure</i> , 2004, 10, 339-343.	0.7	14
65	Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique survey. <i>Haemophilia</i> , 2021, 27, 957-966.	1.0	14
66	Preferences for vaccines against children's diarrheal illness among mothers in Poland and Hungary. <i>Vaccine</i> , 2018, 36, 6022-6029.	1.7	13
67	Quantitative Benefit-Risk Assessment: State of the Practice Within Industry. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 415-425.	0.8	13
68	Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. <i>Patient</i> , 2012, 5, 265-278.	1.1	12
69	Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 259-269.	1.7	12
70	Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional survey. <i>Supportive Care in Cancer</i> , 2018, 26, 251-260.	1.0	12
71	Parkinson's Patients' Tolerance for Risk and Willingness to Wait for Potential Benefits of Novel Neurostimulation Devices: A Patient-Centered Threshold Technique Study. <i>MDM Policy and Practice</i> , 2021, 6, 238146832097840.	0.5	12
72	Patients' Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus Infection. <i>Patient</i> , 2012, 5, 265-278.	1.1	12

#	ARTICLE	IF	CITATIONS
73	Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings. <i>Supportive Care in Cancer</i> , 2009, 17, 405-411.	1.0	11
74	Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. <i>Patient</i> , 2016, 9, 323-333.	1.1	11
75	Hemodialysis patients' preferences for the management of secondary hyperparathyroidism. <i>BMC Nephrology</i> , 2017, 18, 254.	0.8	10
76	Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 201.	1.0	9
77	<p>The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 2093-2104.	0.8	9
78	Physicians' stated trade-off preferences for chronic hepatitis B treatment outcomes in Germany, France, Spain, Turkey, and Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 1.	0.8	9
79	Issues that May Affect the Validity and Reliability of Willingness-to-Pay Estimates in Stated-Preference Studies. <i>Patient</i> , 2008, 1, 249-250.	1.1	8
80	The effect of information on preferences for treatments of metastatic renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2016, 32, 1827-1838.	0.9	8
81	<p>From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 1093-1110.	0.8	8
82	A revealed preference analysis to develop composite scores approximating lung allocation policy in the U.S. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 8.	1.5	8
83	Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. <i>Frontiers in Medicine</i> , 2021, 8, 595797.	1.2	8
84	Treatment preferences for preventive interventions for rheumatoid arthritis: protocol of a mixed methods case study for the Innovative Medicines Initiative PREFER project. <i>BMJ Open</i> , 2021, 11, e045851.	0.8	8
85	Hemodialysis patients' preferences for the management of anemia. <i>BMC Nephrology</i> , 2017, 18, 253.	0.8	7
86	Patient-Centered Identification of Meaningful Regulatory Endpoints for Medical Devices to Treat Parkinson's Disease. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110213.	0.5	7
87	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. <i>European Journal of Pain</i> , 2022, 26, 648-667.	1.4	7
88	Benefit-risk tradeoff preferences for chronic hand eczema treatments. <i>Journal of Dermatological Treatment</i> , 2017, 28, 40-46.	1.1	6
89	Improvements to Survey Design from Pilot Testing a Discrete-Choice Experiment of the Preferences of Persons Living with HIV for Long-Acting Antiretroviral Therapies. <i>Patient</i> , 2022, 15, 513-520.	1.1	6
90	Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom. <i>BMC Health Services Research</i> , 2018, 18, 518.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Assessing Payers'™ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. <i>Value in Health</i> , 2022, 25, 443-450.	0.1	4
92	Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	1.1	4
93	Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure. <i>Current Medical Research and Opinion</i> , 2017, 33, 2027-2038.	0.9	3
94	Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study. <i>Journal of Dermatological Treatment</i> , 2021, , 1-8.	1.1	3
95	Estimating conditional certainty equivalents using choice-experiment data. <i>Journal of Choice Modelling</i> , 2015, 15, 14-25.	1.2	2
96	CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. <i>Future Oncology</i> , 2021, 17, 4697-4709.	1.1	2
97	Japanese Patients'™ and Physicians'™ Preferences for Anticoagulant Use in Atrial Fibrillation: Results from a Discrete-choice Experiment. <i>Journal of Health Economics and Outcomes Research</i> , 2014, 2, 207-220.	0.6	2
98	Economic evaluation of OROS® hydromorphone for chronic pain: A Pan-European perspective. <i>Journal of Opioid Management</i> , 2011, 7, 287-296.	0.2	2
99	Patients Are Willing to Trade off Efficacy, Safety, and Administration Attributes of Chronic Idiopathic Purpura (ITP) Therapy: Results from a Large North American Discrete Choice Study. <i>Blood</i> , 2008, 112, 669-669.	0.6	2
100	The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. <i>AIDS Research and Therapy</i> , 2022, 19, 13.	0.7	2
101	The Patient Voice: Exploring Treatment Preferences in Participants with Mild Cognitive Concerns to Inform Regulatory Decision Making. <i>Patient</i> , 2022, , .	1.1	2
102	Patients' Self-Reported Value of Avoiding Key Heart Failure Outcomes Differs Based on Disease Knowledge. <i>Journal of Cardiac Failure</i> , 2016, 22, S100.	0.7	1
103	Quantifying what matters most to patients and care partners in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040095.	0.4	1
104	Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e040100.	0.4	1
105	<p>Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1049-1064.	0.8	1
106	Communicating Test Results from a General Health Check: Preferences from a Discrete Choice Experiment Survey. <i>Patient</i> , 2021, 14, 649-660.	1.1	1
107	Design and evaluation of strategies to implement HIV prevention interventions for pregnant women in community pharmacy settings in western Kenya: a mixed-methods study protocol. <i>BMJ Open</i> , 2021, 11, e052311.	0.8	1
108	Stated preferences of patients with cancer for health-related quality-of-life domains during treatment. <i>Clinical Therapeutics</i> , 2003, 25, D22-D24.	1.1	0

#	ARTICLE	IF	CITATIONS
109	Exploring Decisional Conflict With Measures of Numeracy and Optimism in a Stated Preference Survey. MDM Policy and Practice, 2021, 6, 238146832110586.	0.5	0
110	Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights. Pharmacoeconomics, 0, , .	1.7	0